Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Estimated Market Size and CAGR of the Dyslipidemia Market for the Period 2025–2029?
The dyslipidemia market size has grown strongly in recent years. It will grow from $16.31 billion in 2024 to $17.91 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rising genetic predisposition, increasing sedentary lifestyle, rising unhealthy diet, growing aging population, and increasing obesity rates.
The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to " $26.43 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to growing advancements in lipid-lowering therapies, growing awareness and screening programs, rising prevalence of metabolic disorders, increasing healthcare expenditure, and rising prevalence of dyslipidemia. Major trends in the forecast period include advancement in gene therapies, innovation in RNA-based treatments, advancement in AI-driven drug discovery, advancement in personalized medicine, and innovation in digital health monitoring.
Get your free report sample today:
Which Factors Are Contributing Most to the Expansion of the Dyslipidemia Market?
The increasing obese population is expected to propel the growth of the dyslipidemia market going forward. The obese population refers to individuals who have excess body fat that may negatively impact their health. The obese population is increasing as lifestyle shifts cause prolonged energy imbalances, resulting in gradual weight gain and related health issues. Obesity causes dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels that increase the risk of cardiovascular diseases. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately one in eight people worldwide struggle with obesity, including 2.5 billion adults aged 18 and older. Additionally, the number of overweight children under five years old reached 37 million. Therefore, the increasing obese population drives the dyslipidemia market.
What Are the Emerging Segments Driving Growth in the Dyslipidemia Market?
The dyslipidemiamarket covered in this report is segmented –
1) By Treatment: Statins; Bile Acid Sequestrants; PCSK9 Inhibitors; Small Interfering RNA (siRNA); Cholesterol Absorption Inhibitors; Fibrates; Niacins; Omega-3 Fatty Acid Derivatives; Other Treatments
2) By Route Of Administration: Oral; Parental
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Store; Online Pharmacies
Subsegments:
1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
2) By Bile Acid Sequestrants: Cholestyramine; Colesevelam
3) By PCSK9 Inhibitors: Evolocumab; Alirocumab
4) By Small Interfering RNA (siRNA): Inclisiran
5) By Cholesterol Absorption Inhibitors: Ezetimibe
6) By Fibrates: Fenofibrate; Gemfibrozil
7) By Niacins: Nicotinic Acid
8) By Omega-3 Fatty Acid Derivatives: Eicosapentaenoic Acid (EPA); Docosahexaenoic Acid (DHA)
9) By Other Treatments: Herbal Supplements; Combination Therapies
Which Major Trends Are Expected to Define the Dyslipidemia Market Through 2029?
Major companies operating in the dyslipidemia market are focusing on developing advanced combination therapies to enhance treatment efficacy, improve patient compliance, and address multiple lipid abnormalities simultaneously. Advanced combination therapies refer to treatment approaches that use two or more therapeutic agents in a single regimen to improve efficacy, reduce side effects, and target multiple disease mechanisms simultaneously. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company announced NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) approved by the Food and Drug Administration, a US-based government agency. These advanced non-statin oral medications are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The new labels allow for the use of NEXLETOL and NEXLIZET either alone or in combination with statins, which are commonly used cholesterol-lowering drugs. This flexibility is particularly beneficial for patients who cannot tolerate statins or prefer non-statin options.
Which Companies Hold a Prominent Position in the Dyslipidemia Market?
Major companies operating in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical
Get the detailed dyslipidemia market report today
What Are the Fastest-Growing Regions in the Dyslipidemia Market?
North America was the largest region in the dyslipidemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyslipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment